QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zondor, S. D Articles by Medina, P. J Search for Related Content PubMed PubMed Citation Articles by Zondor, S. D Articles by Medina, P. J

NEW DRUG DEVELOPMENTS

Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other Malignancies

Oncology Pharmacotherapy Resident, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Patrick J Medina, PharmD BCOP

Assistant Professor, College of Pharmacy, University of Oklahoma Health Sciences Center

Reprints: Stacey D Zondor PharmD, College of Pharmacy, University of Oklahoma Health Sciences Center, 1110 N. Stonewall, PO Box 26901, Oklahoma City, OK 73190-5040, fax 405/271-6430, stacey-zondor{at}ouhsc.edu

OBJECTIVE: To review the pharmacology, pharmacokinetics, and pivotal clinical trials for bevacizumab, emphasizing its use in colorectal cancer.

DATA SOURCES: A PubMed/MEDLINE search was conducted (1966–April 2004) using the following terms: bevacizumab, Avastin, anti-VEGF, anti-angiogenesis, and colorectal cancer. Additional data sources included meeting abstracts, bibliographies from identified articles, and information from the manufacturer.

STUDY SELECTION AND DATA EXTRACTION: Preclinical and clinical trials that used bevacizumab for the treatment of colorectal cancer and other malignancies were selected from the data sources. All published, randomized clinical trials evaluating bevacizumab in colorectal cancer were included in this review.

DATA SYNTHESIS: Despite advances in chemotherapy, current therapeutic options for metastatic disease provide only temporary benefit for most patients. Bevacizumab is the first anti-cancer agent shown to provide benefit for patients with cancer by inhibiting angiogenesis. Bevacizumab has shown significant activity in the treatment of many cancers, including metastatic colorectal cancer. When used in combination with fluorouracil-based chemotherapy, bevacizumab improves overall response rates, time to progression, and survival in patients with metastatic colorectal cancer. Common toxicities associated with bevacizumab include hypertension, bleeding episodes, and thrombotic events.

CONCLUSIONS: Although clinical knowledge on the effectiveness of bevacizumab is limited, early data indicate that it is a promising agent, with a novel mechanism of action, for patients with metastatic cancer, including colorectal cancer.

Key Words: anti-angiogenesis, bevacizumab, colorectal cancer

Published Online, June 8, 2004. www.theannals.com, DOI 10.1345/aph.1D470

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-04-025-H01 Bevacizumab (Avastin, Genentech).

This article has been cited by other articles:

				M. Damianovich, M. Blank, A. Raiter, B. Hardy, and Y. Shoenfeld Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg) Int. Immunol., September 1, 2009; 21(9): 1057 - 1063. [Abstract] [Full Text] [PDF]

				E J Chung, S Yoo, H J Lim, S H Byeon, J H Lee, and H J Koh Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib Br J Ophthalmol, July 1, 2009; 93(7): 958 - 963. [Abstract] [Full Text] [PDF]

				S. S. Shord, L. R. Bressler, L. A. Tierney, S. Cuellar, and A. George Understanding and managing the possible adverse effects associated with bevacizumab Am. J. Health Syst. Pharm., June 1, 2009; 66(11): 999 - 1013. [Abstract] [Full Text] [PDF]

				K. R. Molhoek, H. Griesemann, J. Shu, J. E. Gershenwald, D. L. Brautigan, and C. L. Slingluff Jr. Human Melanoma Cytolysis by Combined Inhibition of Mammalian Target of Rapamycin and Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2 Cancer Res., June 1, 2008; 68(11): 4392 - 4397. [Abstract] [Full Text] [PDF]

				E. Dib, M. Maia, I. M. Longo-Maugeri, M. C. Martins, J. S. Mussalem, C. C. Squaiella, F. M. Penha, O. Magalhaes Jr, E. B. Rodrigues, and M. E. Farah Subretinal Bevacizumab Detection after Intravitreous Injection in Rabbits Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1097 - 1100. [Abstract] [Full Text] [PDF]

				M. B. Toma and P. J. Medina Update on Targeted Therapy--Focus on Monoclonal Antibodies Journal of Pharmacy Practice, February 1, 2008; 21(1): 4 - 16. [Abstract] [PDF]

				J. A. Allen, A. Adlakha, and P. R. Bergethon Reversible Posterior Leukoencephalopathy Syndrome After Bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer. Arch Neurol, October 1, 2006; 63(10): 1475 - 1478. [Abstract] [Full Text] [PDF]

				N. Jo, C. Mailhos, M. Ju, E. Cheung, J. Bradley, K. Nishijima, G. S. Robinson, A. P. Adamis, and D. T. Shima Inhibition of Platelet-Derived Growth Factor B Signaling Enhances the Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Multiple Models of Ocular Neovascularization Am. J. Pathol., June 1, 2006; 168(6): 2036 - 2053. [Abstract] [Full Text] [PDF]

				N. Amino, Y. Ideyama, M. Yamano, S. Kuromitsu, K. Tajinda, K. Samizu, H. Hisamichi, A. Matsuhisa, K. Shirasuna, M. Kudoh, et al. YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors Clin. Cancer Res., March 1, 2006; 12(5): 1630 - 1638. [Abstract] [Full Text] [PDF]

				K Gupta and J Zhang Angiogenesis: a curse or cure? Postgrad. Med. J., April 1, 2005; 81(954): 236 - 242. [Abstract] [Full Text] [PDF]